Protein-based drugs constitute around 25% of new approvals and most of them are glycoproteins. Using selected examples of prominent glycoprotein drugs, the course aims at providing insight into glycosylation-activity relationships and into biotechnological production and analytics.
Learning objective
Students gain basic knowledge in "pharmaceutical glycobiology". This implies knowing and understanding: - major mechanisms underlying the roles of glycosylation for the biological/therapeutic actions of glycoproteins (glycosylation-function relationships) using prominent examples of glycoprotein drugs. - the major types of protein-linked glycans and the biosynthetic pathways for their formation - how glycoprotein drugs are produced (including the most important expression systems used), glycoengineered and analysed (quality control). Students are able to apply this knowledge in solving simple problems in glycoprotein drug development (on paper). Students gain the ability to reflect on roles of glycosylation in various biological contexts.
Content
lecture plan: 1. Glycans - information carriers in biology and pharmacotherapy 2. Glucocerebrosidase and the biosynthesis of N-glycans 3. Improving the therapeutic profile of monoclonal antibodies by glycoengineering 4. Mucin-type O-glycans and sialylation as gCQA of glycoprotein hormone drugs 5. production and gCQA analysis of Glucocerebrosidase, monoclonal antibodies, glycoprotein hormone drugs - Glycoanalytics 6. EPO "the same but different"
Lecture notes
The slides used for the lectures will be provided online
Literature
- Essentials of Glycobiology 3rd edition, A. Varki, R.D. Cummings et al., Cold Spring Harbor Laboratory Press, New York 2017. - recent publications as cited/proposed on the lecture slides
Prerequisites / Notice
Requirements: Basic knowledge in immunology, molecular biology, protein and carbohydrate chemistry, analytical techniques. Basic knowledge in pharmacology.